Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
暂无分享,去创建一个
B. Pulendran | J. Bloom | R. Tisch | R. Rappuoli | R. Baric | A. Walls | D. Veesler | L. Carter | Rashmi Ravichandran | N. King | Tyler N. Starr | Allison J. Greaney | M. Navarro | John E. Bowen | M. A. Tortorici | D. Pettie | J. McLellan | C. Hsieh | Kelly D. Smith | D. Fuller | T. Sheahan | Cassandra Ogohara | A. Schäfer | D. Corti | H. Kleanthous | S. Leist | W. V. Van Voorhis | R. G. van der Most | D. Martinez | B. Fiala | F. Villinger | Ralph Baric | Kenneth A. Rogers | David R. Martinez | M. O’Connor | Lisa Shirreff | S. Wrenn | D. O’hagan | Kaitlin R. Sprouse | M. Clark | Marcos C. Miranda | Minh N. Pham | P. Arunachalam | Douglas E. Ferrell | Natalie Brunette | Elizabeth Kepl | Samantha K. Zepeda | Claire Sydeman | Max Johnson | Alyssa Blackstone | S. W. Tilles | D. R. Martinez | Lisa M. Shirreff | Douglas E Ferrell | S. Tilles | Max R. Johnson | Samuel Wrenn | Kelly D. Smith | Sasha W. Tilles | Matthew Clark
[1] A. Telenti,et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 , 2022, bioRxiv.
[2] M. Beltramello,et al. Broad betacoronavirus neutralization by a stem helix–specific human antibody , 2021, Science.
[3] M. Beltramello,et al. Broad sarbecovirus neutralization by a human monoclonal antibody , 2021, Nature.
[4] M. Beltramello,et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.
[5] A. Telenti,et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern , 2021, Science.
[6] J. Bloom,et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection , 2021, Science Translational Medicine.
[7] A. Walls,et al. Structural basis for broad coronavirus neutralization , 2021, Nature Structural & Molecular Biology.
[8] M. Beltramello,et al. A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery , 2021, bioRxiv.
[9] B. Haynes,et al. A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice , 2021, bioRxiv.
[10] M. Nussenzweig,et al. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies , 2021, bioRxiv.
[11] R. Andino,et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant , 2021, Cell.
[12] B. Pulendran,et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity , 2021, Nature.
[13] A. Telenti,et al. Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies , 2021, bioRxiv.
[14] L. Stamatatos,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.
[15] M. Diamond,et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein , 2021, Cell.
[16] M. Beltramello,et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, Cell.
[17] D. Baker,et al. Quadrivalent influenza nanoparticle vaccines induce broad protection , 2021, Nature.
[18] D. Weissman,et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice , 2021, Science.
[19] William T. Harvey,et al. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[20] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[21] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, Nature Medicine.
[22] D. Stuart,et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain , 2021, Cell.
[23] N. Sullivan,et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. , 2021, The New England journal of medicine.
[24] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.
[25] V. Simon,et al. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine , 2021, medRxiv.
[26] M. Edelstein,et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[27] D. Ho,et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, Research square.
[28] M. Diamond,et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail , 2021, bioRxiv.
[29] M. Beltramello,et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity , 2021, Cell.
[30] D. Fremont,et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization , 2021, Cell Host & Microbe.
[31] D. Ho,et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, bioRxiv.
[32] D. Ho,et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.
[33] Lisa E. Gralinski,et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody , 2021, Science.
[34] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.
[35] M. Nussenzweig,et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice , 2020, Science.
[36] J. Bloom,et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies , 2021, bioRxiv.
[37] A. Walls,et al. Structural basis for broad coronavirus neutralization , 2020, Nature Structural & Molecular Biology.
[38] Rommie E. Amaro,et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma , 2020, bioRxiv.
[39] Carl A. B. Pearson,et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England , 2020, medRxiv.
[40] D. Stuart,et al. The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain , 2020, SSRN Electronic Journal.
[41] Sergei L. Kosakovsky Pond,et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.
[42] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[43] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[44] J. Bloom,et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2020, bioRxiv.
[45] Sarah K. Hilton,et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, Cell Host & Microbe.
[46] W. P. Duprex,et al. Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape , 2020, bioRxiv.
[47] Lisa E. Gralinski,et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo , 2020, Science.
[48] Gaurav D. Gaiha,et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.
[49] E. Fischer,et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.
[50] Lisa E. Gralinski,et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 , 2020, Cell.
[51] V. Munster,et al. Case Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient. Avanzato, et al. , 2020 .
[52] Vineet D. Menachery,et al. Spike mutation D614G alters SARS-CoV-2 fitness , 2020, Nature.
[53] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[54] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[55] G. Atwal,et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, Science.
[56] E. Holmes,et al. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein , 2020, Current Biology.
[57] M. Beltramello,et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms , 2020, Science.
[58] Lisa E. Gralinski,et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice , 2020, Cell.
[59] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[60] Pardis C Sabeti,et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant , 2020, Cell.
[61] D. Lauffenburger,et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters , 2020, Nature medicine.
[62] Vineet D. Menachery,et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility , 2020, Nature.
[63] Lisa E. Gralinski,et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.
[64] Lisa E. Gralinski,et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 , 2020, Cell.
[65] J. Mascola,et al. SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.
[66] J. Mascola,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.
[67] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[68] Ilya J. Finkelstein,et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.
[69] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[70] R. Dutch. Faculty Opinions recommendation of Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[71] Xuguang Li,et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity , 2020, Cell.
[72] Lisa E. Gralinski,et al. Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.
[73] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[74] Pardis C Sabeti,et al. Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant , 2020, bioRxiv.
[75] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[76] R. Owens,et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike , 2020, Cell Host & Microbe.
[77] Jesse D. Bloom,et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding , 2020, bioRxiv.
[78] G. Atwal,et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.
[79] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[80] J. Dye,et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.
[81] A. Basu,et al. Faculty Opinions recommendation of SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[82] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.
[83] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[84] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[85] Alice C Hughes,et al. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein , 2020, Current Biology.
[86] J. Bloom,et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays , 2020, bioRxiv.
[87] K. Yuen,et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.
[88] I. Wilson,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[89] Linqi Zhang,et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.
[90] Jia-Fu Jiang,et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins , 2020, Nature.
[91] K. Shi,et al. Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.
[92] Nicholas C. Wu,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[93] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[94] Qiang Zhou,et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.
[95] M. Letko,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[96] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[97] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[98] P. Bjorkman,et al. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers , 2020, bioRxiv.
[99] D. Veesler,et al. Structural insights into coronavirus entry , 2019, Advances in Virus Research.
[100] A. Walls,et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.
[101] U. Baxa,et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses , 2018, Nature Immunology.
[102] J. Plotkin,et al. Inferring the shape of global epistasis , 2018, Proceedings of the National Academy of Sciences.
[103] Conrad C. Huang,et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis , 2018, Protein science : a publication of the Protein Society.
[104] Barney S. Graham,et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.
[105] G. Whittaker,et al. Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection. , 2016, Bio-protocol.
[106] David Baker,et al. Accurate design of megadalton-scale two-component icosahedral protein complexes , 2016, Science.
[107] Lisa E. Gralinski,et al. SARS-like WIV1-CoV poised for human emergence , 2016, Proceedings of the National Academy of Sciences.
[108] F. Dimaio,et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer , 2016, Nature.
[109] Lisa E. Gralinski,et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.
[110] Lisa E. Gralinski,et al. A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.
[111] Y. Matsuura,et al. Acquisition of Complement Resistance through Incorporation of CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64 , 2010, Journal of Virology.
[112] D. G. Gibson,et al. Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.
[113] R. Baric,et al. Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.
[114] Ralph Baric,et al. A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice , 2007, PLoS pathogens.
[115] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[116] Nuno R. Faria,et al. Genomic characterisation of an emergent SARS- CoV-2 lineage in Manaus: preliminary findings , 2021 .